Alumis Q2 net loss $56.5M, cash $209.5M; Phase 3 psoriasis trial initiated

ALUMIS INC.

2024-Q2 EPS reported -$44.17

Net loss $56.5M for Q2 2024 vs $36.3M in Q2 2023; R&D expense $48.6M (up from $32.8M).
Cash and marketable securities $209.5M at June 30; IPO net proceeds $233.2M extend runway into 2026.
Initiated ESK-001 Phase 3 ONWARD program in moderate-to-severe plaque psoriasis; topline expected 2026.
Completed IPO and concurrent private placement raising $250M gross proceeds (15.625M shares at $16.00).
Phase 1 trial for A-005 (CNS-penetrant TYK2 inhibitor) dosed first healthy volunteer in April 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.